CVE:NVHNovoheart Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Novoheart Holdings Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add C$0.38 -0.01 (-2.56 %) (As of 06/3/2020 04:00 PM ET) Add Compare Share Today's RangeC$0.38Now: C$0.38▼C$0.3950-Day RangeC$0.37MA: C$8,802.32▼C$440,095.0052-Week RangeC$0.21Now: C$0.38▼C$0.72Volume13,500 shsAverage Volume35,301 shsMarket CapitalizationC$71.68 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsInsider TradesHeadlinesSocial Media Novoheart Holdings Inc. operates as a stem cell biotechnology company in the United States, Canada, and Hong Kong. It offers an array of next-generation human heart tissue prototypes. The company provides a range of bioengineering technologies known as the MyHeart platform, including the human mini-heart 'novoHeart' that is capable of pumping and ejecting fluid. Its MyHeart platform develops cell-based cardiac regenerative therapies. The company's MyHeart products include human pluripotent stem cell-derived cardiomyocytes, human ventricular cardiac anisotropic sheet assays, and human ventricular cardiac tissue strips assays. It also provides screening and phenotyping services; and consultation services, including mapping and designing preclinical studies that involve human embryonic or induced pluripotent stem cell-derived cardiomyocytes, prototyping custom bioreactor designs, and developing custom software for streamlining of screening platforms and analysis of acquired data. The company is based in Vancouver, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Novoheart. Previous Next 2.6 Community Rank Outperform VotesNovoheart has received 33 “outperform” votes. (Add your “outperform” vote.)Underperform VotesNovoheart has received 30 “underperform” votes. (Add your “underperform” vote.)Community SentimentNovoheart has received 52.38% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Novoheart and other stocks. Vote “Outperform” if you believe NVH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NVH will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldNovoheart does not currently pay a dividend.Dividend GrowthNovoheart does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Novoheart insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Novoheart is -8.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Novoheart is -8.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNovoheart has a P/B Ratio of 2.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.52 out of 5 stars Industry, Sector and Symbol Stock Exchange CVE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolCVE:NVH Previous Symbol CUSIPN/A CIKN/A Webwww.novoheart.com Phone604-398 3170Debt Debt-to-Equity Ratio27.83 Current Ratio7.86 Quick Ratio7.72Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesC$435,659.00 Price / Sales164.54 Cash FlowC$0.09 per share Price / Cash Flow4.20 Book ValueC$0.13 per share Price / Book2.84Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares188,641,000Market CapC$71.68 million Next Earnings DateN/A OptionableNot Optionable TSXV:NVH Rates by TradingView Receive NVH News and Ratings via Email Sign-up to receive the latest news and ratings for NVH and its competitors with MarketBeat's FREE daily newsletter. Novoheart (CVE:NVH) Frequently Asked Questions How has Novoheart's stock been impacted by COVID-19 (Coronavirus)? Novoheart's stock was trading at C$0.65 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NVH stock has decreased by 41.5% and is now trading at C$0.38. View which stocks have been most impacted by Coronavirus. Has Novoheart been receiving favorable news coverage? Media headlines about NVH stock have been trending very negative this week, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Novoheart earned a news sentiment score of -3.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future. View the latest news aboutNovoheart. Who are some of Novoheart's key competitors? Some companies that are related to Novoheart include Medicenna Therapeutics (MDNA), ProMetic Life Sciences (PLI), IMV (IMV), Emblem (EMC), Exicure (XCUR), Pfenex (PFNX), Novacyt (NCYT), Fennec Pharmaceuticals (FRX), Bioventix (BVXP), Exicure (XCUR), Enochian Biosciences (ENOB), Antibe Therapeutics (ATE), Ergomed (ERGO), Theratechnologies (TH) and Rafael (RFL). View all competitors. What other stocks do shareholders of Novoheart own? Based on aggregate information from My MarketBeat watchlists, some companies that other Novoheart investors own include InVitae (NVTA) and Natera (NTRA). Who are Novoheart's key executives? Novoheart's management team includes the following people: Dr. Ronald Li B.Sc. (Hons), Ph.D., Scientific Co-Founder, CEO & Director (Age 48)Prof. Kevin Costa B.S., Ph.D., Chief Scientific Officer & Scientific Co-Founder (Age 53)Dr. Camie Chan B.S., B.Sc. (Hons), M.Sc., Ph.D., Interim CFO, COO, Corp. Sec. & Director (Age 45)Prof. Michelle Khine, Scientific Co-Founder & Member of Scientific Advisory BoardDr. Bill A. Williams, Sr. VP of Commercial Operations What is Novoheart's stock symbol? Novoheart trades on the Canadian Venture Exchange (CVE) under the ticker symbol "NVH." How do I buy shares of Novoheart? Shares of NVH and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. What is Novoheart's stock price today? One share of NVH stock can currently be purchased for approximately C$0.38. How big of a company is Novoheart? Novoheart has a market capitalization of C$71.68 million and generates C$435,659.00 in revenue each year. What is Novoheart's official website? The official website for Novoheart is www.novoheart.com. How can I contact Novoheart? The company can be reached via phone at 604-398 3170. This page was last updated on 6/3/2020 by MarketBeat.com Staff
